Which has better valuation & earnings, BRKR or RVTY?

Revvity has lower revenue, but higher earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bruker $3.44B 2.59 -$8.60M -$0.70 N/A Revvity $2.86B 4.58 $241.20M $2.10 55.85

Is BRKR or RVTY more profitable?

Revvity has a net margin of 8.16% compared to Bruker's net margin of -2.35%. Bruker's return on equity of 12.47% beat Revvity's return on equity. Company Net Margins Return on Equity Return on Assets Bruker -2.35% 12.47% 4.91% Revvity 8.16% 8.34% 5.01%

Does the media favor BRKR or RVTY?

In the previous week, Revvity had 1 more articles in the media than Bruker. MarketBeat recorded 7 mentions for Revvity and 6 mentions for Bruker. Revvity's average media sentiment score of 1.14 beat Bruker's score of 0.84 indicating that Revvity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bruker 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revvity 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, RVTY or TECH?

Revvity has higher revenue and earnings than Bio-Techne. Revvity is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revvity $2.86B 4.58 $241.20M $2.10 55.85 Bio-Techne $1.22B 9.27 $73.40M $0.69 104.66

Is RVTY or TECH more profitable?

Bio-Techne has a net margin of 9.05% compared to Revvity's net margin of 8.16%. Bio-Techne's return on equity of 13.57% beat Revvity's return on equity. Company Net Margins Return on Equity Return on Assets Revvity 8.16% 8.34% 5.01% Bio-Techne 9.05% 13.57% 10.66%

Does the media prefer RVTY or TECH?

In the previous week, Bio-Techne had 12 more articles in the media than Revvity. MarketBeat recorded 19 mentions for Bio-Techne and 7 mentions for Revvity. Bio-Techne's average media sentiment score of 1.25 beat Revvity's score of 1.14 indicating that Bio-Techne is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 7 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RVTY or A?

In the previous week, Agilent Technologies had 3 more articles in the media than Revvity. MarketBeat recorded 10 mentions for Agilent Technologies and 7 mentions for Revvity. Revvity's average media sentiment score of 1.14 beat Agilent Technologies' score of 1.06 indicating that Revvity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agilent Technologies 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BIO or RVTY?

In the previous week, Bio-Rad Laboratories had 3 more articles in the media than Revvity. MarketBeat recorded 10 mentions for Bio-Rad Laboratories and 7 mentions for Revvity. Revvity's average media sentiment score of 1.14 beat Bio-Rad Laboratories' score of 0.83 indicating that Revvity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Rad Laboratories 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revvity 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RVTY or CRL?

In the previous week, Charles River Laboratories International had 15 more articles in the media than Revvity. MarketBeat recorded 22 mentions for Charles River Laboratories International and 7 mentions for Revvity. Revvity's average media sentiment score of 1.14 beat Charles River Laboratories International's score of 0.58 indicating that Revvity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Charles River Laboratories International 10 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Revvity (RVTY) Competitors

$117.29 -0.59 (-0.50%)

As of 02:52 PM Eastern

Compare

RVTY vs. BRKR, TECH, A, BIO, and CRL

Should you buy Revvity stock or one of its competitors? Revvity's main competitors and comparable companies include Bruker (BRKR), Bio-Techne (TECH), Agilent Technologies (A), Bio-Rad Laboratories (BIO), and Charles River Laboratories International (CRL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Revvity compare to Bruker?

Bruker (NASDAQ:BRKR) and Revvity (NYSE:RVTY) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Bruker pays out -28.6% of its earnings in the form of a dividend. Revvity pays out 13.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bruker is clearly the better dividend stock, given its higher yield and lower payout ratio.

Revvity has lower revenue, but higher earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.44B	2.59	-$8.60M	-$0.70	N/A
Revvity	$2.86B	4.58	$241.20M	$2.10	55.85

Bruker presently has a consensus price target of $56.64, suggesting a potential downside of 3.15%. Revvity has a consensus price target of $108.36, suggesting a potential downside of 7.61%. Given Bruker's stronger consensus rating and higher probable upside, research analysts plainly believe Bruker is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.57
Revvity	0 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Revvity has a net margin of 8.16% compared to Bruker's net margin of -2.35%. Bruker's return on equity of 12.47% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bruker	-2.35%	12.47%	4.91%
Revvity	8.16%	8.34%	5.01%

In the previous week, Revvity had 1 more articles in the media than Bruker. MarketBeat recorded 7 mentions for Revvity and 6 mentions for Bruker. Revvity's average media sentiment score of 1.14 beat Bruker's score of 0.84 indicating that Revvity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bruker	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revvity	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.5% of Bruker shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 27.2% of Bruker shares are owned by insiders. Comparatively, 0.9% of Revvity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bruker has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, Revvity has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Summary

Bruker beats Revvity on 10 of the 19 factors compared between the two stocks.

How does Revvity compare to Bio-Techne?

Revvity (NYSE:RVTY) and Bio-Techne (NASDAQ:TECH) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

86.7% of Revvity shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 0.9% of Revvity shares are owned by insiders. Comparatively, 1.3% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Bio-Techne had 12 more articles in the media than Revvity. MarketBeat recorded 19 mentions for Bio-Techne and 7 mentions for Revvity. Bio-Techne's average media sentiment score of 1.25 beat Revvity's score of 1.14 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	7 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revvity currently has a consensus target price of $108.36, indicating a potential downside of 7.61%. Bio-Techne has a consensus target price of $68.92, indicating a potential downside of 4.56%. Given Bio-Techne's higher probable upside, analysts clearly believe Bio-Techne is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Bio-Techne	1 Sell rating(s)	14 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06

Bio-Techne has a net margin of 9.05% compared to Revvity's net margin of 8.16%. Bio-Techne's return on equity of 13.57% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.16%	8.34%	5.01%
Bio-Techne	9.05%	13.57%	10.66%

Revvity has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

Revvity has higher revenue and earnings than Bio-Techne. Revvity is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	4.58	$241.20M	$2.10	55.85
Bio-Techne	$1.22B	9.27	$73.40M	$0.69	104.66

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Revvity pays out 13.3% of its earnings in the form of a dividend. Bio-Techne pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Bio-Techne beats Revvity on 12 of the 18 factors compared between the two stocks.

How does Revvity compare to Agilent Technologies?

Revvity (NYSE:RVTY) and Agilent Technologies (NYSE:A) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

Revvity has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market.

Agilent Technologies has a net margin of 19.55% compared to Revvity's net margin of 8.16%. Agilent Technologies' return on equity of 24.33% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.16%	8.34%	5.01%
Agilent Technologies	19.55%	24.33%	12.99%

Agilent Technologies has higher revenue and earnings than Revvity. Agilent Technologies is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	4.58	$241.20M	$2.10	55.85
Agilent Technologies	$6.95B	6.05	$1.30B	$4.98	29.89

Revvity presently has a consensus target price of $108.36, suggesting a potential downside of 7.61%. Agilent Technologies has a consensus target price of $160.24, suggesting a potential upside of 7.65%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Agilent Technologies is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89

86.7% of Revvity shares are owned by institutional investors. 0.9% of Revvity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.7%. Revvity pays out 13.3% of its earnings in the form of a dividend. Agilent Technologies pays out 20.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has raised its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Agilent Technologies had 3 more articles in the media than Revvity. MarketBeat recorded 10 mentions for Agilent Technologies and 7 mentions for Revvity. Revvity's average media sentiment score of 1.14 beat Agilent Technologies' score of 1.06 indicating that Revvity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilent Technologies	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Agilent Technologies beats Revvity on 15 of the 20 factors compared between the two stocks.

How does Revvity compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO) and Revvity (NYSE:RVTY) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 0.9% of Revvity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Bio-Rad Laboratories has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Revvity has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Bio-Rad Laboratories has a net margin of 8.59% compared to Revvity's net margin of 8.16%. Revvity's return on equity of 8.34% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	8.59%	3.54%	2.48%
Revvity	8.16%	8.34%	5.01%

Bio-Rad Laboratories has higher earnings, but lower revenue than Revvity. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	3.71	$759.90M	$8.25	43.46
Revvity	$2.86B	4.58	$241.20M	$2.10	55.85

Bio-Rad Laboratories currently has a consensus target price of $343.33, indicating a potential downside of 4.23%. Revvity has a consensus target price of $108.36, indicating a potential downside of 7.61%. Given Bio-Rad Laboratories' higher probable upside, equities analysts plainly believe Bio-Rad Laboratories is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Revvity	0 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Bio-Rad Laboratories had 3 more articles in the media than Revvity. MarketBeat recorded 10 mentions for Bio-Rad Laboratories and 7 mentions for Revvity. Revvity's average media sentiment score of 1.14 beat Bio-Rad Laboratories' score of 0.83 indicating that Revvity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revvity	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Revvity beats Bio-Rad Laboratories on 10 of the 16 factors compared between the two stocks.

How does Revvity compare to Charles River Laboratories International?

Revvity (NYSE:RVTY) and Charles River Laboratories International (NYSE:CRL) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Revvity has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

Revvity presently has a consensus target price of $108.36, indicating a potential downside of 7.61%. Charles River Laboratories International has a consensus target price of $255.65, indicating a potential downside of 9.18%. Given Revvity's higher probable upside, research analysts plainly believe Revvity is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

86.7% of Revvity shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 0.9% of Revvity shares are owned by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Charles River Laboratories International had 15 more articles in the media than Revvity. MarketBeat recorded 22 mentions for Charles River Laboratories International and 7 mentions for Revvity. Revvity's average media sentiment score of 1.14 beat Charles River Laboratories International's score of 0.58 indicating that Revvity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	10 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revvity has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	4.58	$241.20M	$2.10	55.85
Charles River Laboratories International	$4.02B	3.35	-$144.34M	-$4.85	N/A

Revvity has a net margin of 8.16% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.16%	8.34%	5.01%
Charles River Laboratories International	-5.96%	15.75%	6.51%

Summary

Charles River Laboratories International beats Revvity on 9 of the 16 factors compared between the two stocks.

Get Revvity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVTY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVTY vs. The Competition

Export

Metric	Revvity	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$13.07B	$9.52B	$7.03B	$24.24B
Dividend Yield	0.24%	1.46%	2.58%	3.70%
P/E Ratio	55.79	62.26	269.09	30.31
Price / Sales	4.58	105.64	642.14	17.89
Price / Cash	13.13	26.06	70.59	33.27
Price / Book	1.81	38.29	13.28	6.57
Net Income	$241.20M	$56.66B	$3.45B	$1.06B
7 Day Performance	2.38%	4.30%	2.17%	1.06%
1 Month Performance	5.74%	2.81%	1.25%	2.94%
1 Year Performance	29.02%	19.78%	68.01%	17.23%

Revvity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVTY Revvity	3.2007 of 5 stars	$117.29 -0.5%	$108.36 -7.6%	+33.7%	$13.07B	$2.86B	55.79	11,000	Positive News
BRKR Bruker	2.6473 of 5 stars	$56.32 +5.4%	$56.64 +0.6%	+83.2%	$8.13B	$3.50B	N/A	11,085
TECH Bio-Techne	2.8571 of 5 stars	$72.12 -0.2%	$68.08 -5.6%	+36.7%	$11.32B	$1.22B	104.52	3,100	Trending News Earnings Report Dividend Announcement Analyst Downgrade
A Agilent Technologies	4.7735 of 5 stars	$148.42 +1.7%	$159.35 +7.4%	+26.4%	$41.23B	$6.95B	29.80	18,100	Positive News Analyst Forecast
BIO Bio-Rad Laboratories	1.9655 of 5 stars	$353.82 +0.4%	$343.33 -3.0%	+31.7%	$9.43B	$2.58B	42.89	7,450	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RVTY) was last updated on 8/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Revvity (RVTY) Competitors

RVTY vs. BRKR, TECH, A, BIO, and CRL

How does Revvity compare to Bruker?

Summary

How does Revvity compare to Bio-Techne?

Summary

How does Revvity compare to Agilent Technologies?

Summary

How does Revvity compare to Bio-Rad Laboratories?

Summary

How does Revvity compare to Charles River Laboratories International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVTY vs. The Competition

Revvity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Revvity (RVTY) Competitors

RVTY vs. BRKR, TECH, A, BIO, and CRL

How does Revvity compare to Bruker?

Is BRKR or RVTY a better dividend stock?

Which has better valuation & earnings, BRKR or RVTY?

Do analysts recommend BRKR or RVTY?

Is BRKR or RVTY more profitable?

Does the media favor BRKR or RVTY?

Do insiders & institutionals believe in BRKR or RVTY?

Which has more risk and volatility, BRKR or RVTY?

Summary

How does Revvity compare to Bio-Techne?

Do insiders & institutionals have more ownership in RVTY or TECH?

Does the media prefer RVTY or TECH?

Do analysts rate RVTY or TECH?

Is RVTY or TECH more profitable?

Which has more volatility and risk, RVTY or TECH?

Which has stronger earnings & valuation, RVTY or TECH?

Is RVTY or TECH a better dividend stock?

Summary

How does Revvity compare to Agilent Technologies?

Which has more volatility & risk, RVTY or A?

Is RVTY or A more profitable?

Which has higher valuation and earnings, RVTY or A?

Do analysts recommend RVTY or A?

Do institutionals and insiders believe in RVTY or A?

Is RVTY or A a better dividend stock?

Does the media favor RVTY or A?

Summary

How does Revvity compare to Bio-Rad Laboratories?

Do insiders and institutionals believe in BIO or RVTY?

Which has more risk and volatility, BIO or RVTY?

Is BIO or RVTY more profitable?

Which has higher earnings & valuation, BIO or RVTY?

Do analysts rate BIO or RVTY?

Does the media prefer BIO or RVTY?

Summary

How does Revvity compare to Charles River Laboratories International?

Which has more risk and volatility, RVTY or CRL?

Do analysts recommend RVTY or CRL?

Do institutionals & insiders believe in RVTY or CRL?

Does the media favor RVTY or CRL?

Which has better earnings & valuation, RVTY or CRL?

Is RVTY or CRL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVTY vs. The Competition

Revvity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools